Results 261 to 270 of about 60,209 (283)
Some of the next articles are maybe not open access.
Sirolimus and islet transplants
Transplantation Proceedings, 2003IMMUNOSUPPRESSION is a critical determinant of the success of islet transplants. Tailoring immunosuppression to the specific setting of marginal mass islet cell transplants in autoimmune type 1 diabetic recipients would likely increase the safety, success rate, and applicability of such transplants.
M. Wijkstrom, B.J. Hering
openaire +3 more sources
Pharmacokinetics and Metabolism of Sirolimus
Therapeutic Drug Monitoring, 2000Sirolimus (rapamycin, Rapamune) is a potent immunosuppressive drug that received marketing approval from the US Food and Drug Administration on September 15, 1999. Research into defining its pharmacokinetic (PK) behavior, interaction with other agents, and metabolism is ongoing.
Heather Gallant-Haidner +3 more
openaire +3 more sources
Sirolimus Monotherapy in Liver Transplantation
Transplantation Proceedings, 2007Since 1999, a new immunosuppressive drug was administered to renal transplant patients. The SRL molecule acts by blocking post-receptor signal transduction of interleukin-2 (IL-2) interacting with a family of intracellular binding proteins termed immunophilins FKBPs. Among these FKBPs, FK506 12-kd binding protein is the most relevant.
F. D. Benedetto +9 more
openaire +4 more sources
Sirolimus in liver transplantation
Transplantation Proceedings, 2003Since its introduction in renal transplantation in 1999, sirolimus is being used by an increasing number of liver transplant centers. Compared to the calcineurin inhibitors, sirolimus acts through a separate signal transduction pathway and has a myriad of important biologic effects including: inhibition of lymphocyte proliferation, inhibition of ...
openaire +3 more sources
An immunoassay for the measurement of sirolimus
Clinical Therapeutics, 2000This study assessed the performance characteristics of a new microparticle enzyme immunoassay (MEIA) for the determination of sirolimus in whole blood.In clinical investigatory studies, dose adjustments of the immunosuppressive drug sirolimus have been carried out using either high-performance liquid chromatography (HPLC) or, more recently, this ...
David W. Holt +6 more
openaire +3 more sources
Sirolimus in Pediatric Renal Transplantation
Transplantation Proceedings, 2004Side effects of calcineurin inhibitors (CNIs) include nephrotoxicity and hypertension. Moreover, children have a higher risk of infections and posttransplantation lymphoproliferative disorders. We retrospectively evaluated the efficacy and safety of Sirolimus (SRL) in 18 patients, who were 10.52 +/- 5.03 years at time of transplantation and received a ...
J. Goldberg +4 more
openaire +4 more sources
Sirolimus and everolimus in kidney transplantation
Drug Discovery Today, 2015The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus have shown their efficacy in kidney transplantation, but their wider introduction has been limited by relative high discontinuation rates. Their main advantage compared with calcineurin inhibitors (CNIs) is their relative lack of nephrotoxicity.
Moes, D.J.A.R. +2 more
openaire +4 more sources
Use of sirolimus in kidney transplantation
Progress in Transplantation, 2001Sirolimus, which has a distinctive mechanism of action that inhibits cytokine-driven cell proliferation and maturation, provides an exciting addition to the immunosuppressive regimen for organ transplantation. A significant decrease in the number and severity of rejection episodes has been noted when sirolimus is used; it also offers the potential for
L. Schoenberg, Jeanette M. Podbielski
openaire +3 more sources
Sirolimus: a comprehensive review
Expert Opinion on Pharmacotherapy, 2001Sirolimus (Rapamune), Wyeth-Ayerst, Madison, NJ) is a new, potent, immunosuppressant that is emerging as a foundation for long-term immunosuppressive therapy in renal transplantation. The drug acts during both co-stimulatory activation and cytokine-driven pathways via a unique mechanism: inhibition of a multifunctional serine-threonine kinase ...
openaire +2 more sources
Sirolimus-Induced Isometric Tubular Vacuolization: A New Sirolimus Histopathologic Manifestation
Transplantation Proceedings, 2010The clinical and pathological experience with sirolimus is limited at this time. In this study, we report severe isometric vacuolization of the proximal tubules after sirolimus therapy in two kidney transplant patients. Patient 1 is a hepatitis C virus-positive, 30-year-old African American man who had end-stage renal disease (ESRD) of unknown etiology.
R. Kohli +7 more
openaire +3 more sources